Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290202 | 0.77 | ADRB2 (0.39) | SYKADRB2PRMT5WDR77TDP1 | |
| SCHEMBL387897 | 0.70 | SLC6A3 (0.38) | MEN1RECQLKMT2ATDP1 | |
| SCHEMBL14403134 | 0.70 | SMN1; SMN2 (0.55) | MEN1RECQLKMT2ATDP1 | |
| SCHEMBL387898 | 0.68 | PTGS2 (0.51) | — | |
| SCHEMBL387104 | 0.66 | GAA (0.54) | MEN1RECQLKMT2ATDP1 | |
| SCHEMBL9656885 | 0.65 | SYK (0.45) | SYKADRB2PRMT5WDR77MEN1 | |
| SCHEMBL24795073 | 0.65 | SMN1; SMN2 (0.46) | MEN1KMT2ATDP1 | |
| SCHEMBL22290239 | 0.64 | KDM4E (0.48) | PRMT5WDR77KMT2ATDP1 | |
| SCHEMBL14403225 | 0.64 | ABCG2 (0.54) | MEN1KMT2A | |
| SCHEMBL29288734 | 0.63 | DPP4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298333-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298333-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | PDPK1 1188/4885SYK 2358/4885TGFBR1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.